Meglumina en series terapéuticas de 10 días en niños con leishmaniosis tegumentaria americana

Navarro, Pedro; Martín, Amando; De la Parte, María Antonia; Garrido, Elinor; Robles, Fabián; Silva, Sylvia; Delgado, Olinda; Colmenares, Luis A; Coraspe, Virginia; Ramos, Lucy; Quilarque, Solciet.
Rev. Fac. Med. (Caracas) ; 34(1): 55-59, 2011. tab
Artículo en Español | LILACS | ID: lil-637407

Documentos relacionados

  1. Topical application of ozonated sunflower oil accelerates the healing of lesions of cutaneous leishmaniasis in mice under meglumine antimoniate treatment.
  2. Positivity, diagnosis and treatment follow-up of cutaneous leishmaniasis in war-affected areas of Bajaur, Pakistan.
  3. [Cutaneous leishmaniasis].
  4. Leishmania RNA virus 2 (LRV2) exacerbates dermal lesions caused by Leishmania major and comparatively unresponsive to meglumine antimoniate treatment.
  5. Electrocardiographic Alterations Related to Intralesional Glucantime® Treatments: A Potentially Severe Adverse Event.
  6. Simple and promising paper-based electrochemical platform for serological detection of American tegumentary leishmaniasis.
  7. Large scale systemic control short-circuits pathogen transmission by interrupting the sand rat (Psammomys obesus)-to-sand fly (Phlebotomus papatasi) Leishmania major transmission cycle.
  8. Two small yellowish papules in a 1 year-old boy: cutaneous leishmaniasis.
  9. Efficacy of the treatment using a microemulsion loaded with epoxy-α-lapachone in combination with meglumine antimoniate against murine infection by Leishmania (Leishmania) amazonensis.
  10. Multi-sensorial perceptions of risk: the aesthetics behind (muco)cutaneous leishmaniasis-related stigma in Ecuador.